Johnson & Johnson (JNJ) Com Stk USD 1 (CDI)
- Add to watchlist
- This stock can be held in a
Share news, reports & tips
-
Johnson & Johnson to buy V-Wave for up to $1.7bn
20 August 2024 12:58
(Sharecast News) - Johnson & Johnson said on Tuesday that it has agreed to buy V-Wave, a privately-held company focused on developing treatment options for patients with heart failure, for up to $1.7bn.
-
Johnson & Johnson shares rise on earnings beat despite mixed outlook
17 July 2024 12:34
(Sharecast News) - Johnson & Johnson's stock was in the green on Wednesday, after the pharmaceutical giant reported second-quarter earnings and sales that surpassed analysts' expectations,...
-
Johnson & Johnson proposes $6.5bn deal to settle talc claims
1 May 2024 13:39
(Sharecast News) - Johnson & Johnson has proposed a $6.5bn deal to settle thousands of lawsuits claiming its talc products cause cancer, it was confirmed on Wednesday.
-
Jonnson & Johnson to buy Shockwave Medical for $13.1bn
5 April 2024 12:18
(Sharecast News) - Johnson & Johnson said on Friday that it has agreed to buy Shockwave Medical, which develops products for the treatment of cardiovascular disease, for $13.1bn.
-
US close: Stocks recover from three days of losses
28 March 2024 00:12
(Sharecast News) - Shares on Wall Street showed signs of recovery on Wednesday, with all major indices edging higher amidst low trading volumes following three consecutive down sessions.
-
US close: Stocks mixed ahead of key data releases
24 January 2024 01:09
(Sharecast News) - Wall Street experienced a mixed performance on Tuesday, with its main market indices showing varied results following a record close in the previous session.
-
Johnson & Johnson reports robust quarter, but full-year earnings slip
23 January 2024 12:19
(Sharecast News) - Johnson & Johnson reported robust growth in sales and earnings in its fourth quarter numbers on Tuesday, with sales rising 7.3% year-on-year to $21.4bn.
-
Johnson & Johnson to buy Ambrx for $2bn
8 January 2024 12:35
(Sharecast News) - Johnson & Johnson said on Monday that it has agreed to buy clinical-stage biopharmaceutical company Ambrx for around $2bn.
-
Johnson & Johnson ups guidance after Q3 beat
17 October 2023 11:32
(Sharecast News) - US healthcare giant Johnson & Johnson has upgraded its guidance for the full year after a strong third quarter, which topped analysts' estimates for both sales and profits.
-
Johnson & Johnson lifts guidance after beating Q2 forecasts
20 July 2023 16:36
(Sharecast News) - Johnson & Johnson surpassed expectations with its second-quarter revenue and adjusted earnings on Thursday, after its medtech business experienced a surge in sales.
-
Johnson & Johnson boosts full-year guidance
24 January 2023 07:43
(Sharecast News) - Johnson & Johnson increased its full-year earnings guidance on Tuesday, helped by strong demand for its cancer drugs.
-
Johnson & Johnson to buy Abiomed in $16.6bn deal
1 November 2022 12:24
(Sharecast News) - Johnson & Johnson said on Tuesday that it has agreed to buy heart recovery specialist Abiomed in a $16.6bn deal.
Company announcements Announcements
No company announcements about Johnson & Johnson Com Stk USD 1 (CDI) were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.